Tirzepatide for Obesity Treatment and Diabetes Prevention
Jastreboff AM, le Roux CW, Stefanski A, et al. (2025). New England Journal of Medicine.
Summary
The three-year extension of SURMOUNT-1, reporting on the participants who had prediabetes as well as obesity. It covers weight change to week 176, progression to type 2 diabetes, and safety over the longer period, followed by 17 weeks off treatment, which is the part that shows what happens when the drug stops. The longest published follow-up for this compound; manufacturer-funded, like the parent trial.